Rheumatoid arthritis
Conditions
Interventions
Tocilizumab Treatment Group Intervention: Participants received tocilizumab (dose calculated based on body weight) in combination with methotrexate (10-15 mg/week, at a stable dose) and prednisone ( <
Control Group Intervention: Participants maintained their existing conventional synthetic DMARD (csDMARD) regimen. Adjustments to specific agents or:None
Sponsors
Yuebei People’s Hospital
Eligibility
Sex/Gender
Female
Age
60 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Meet the 2010 ACR/EULAR classification criteria for rheumatoid arthritis. 2. Age >= 60 years. 3. Female sex. 4. Inadequate response (DAS28-ESR >= 5.1 for >=3 months) to >=2 conventional synthetic DMARDs and >=1 TNF-a inhibitor. 5. Anti-CCP antibody level > 3 times the upper limit of normal.
Exclusion criteria
Exclusion criteria: 1. Active infection (including latent tuberculosis without prophylactic treatment); 2. ALT/AST > 3 times the upper limit of normal; 3. Prior use of IL-6 inhibitors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver and kidney function tests;Anti-CCP antibody titer;hs-CRP;IL-6;complete blood count (CBC); | — |
Countries
China
Contacts
Public ContactZhang Beiping
Yuebei People’s Hospital
Outcome results
None listed